GSK
NEWS
Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company’s Executive Committee by Dec. 31, 2017, and leave entirely in early 2018.
GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.
It’s no secret that the life sciences are increasingly international.
Glaxo has a bold future planned for its R&D facility in Maryland.
The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union.
HIV patients have a new maintenance drug in their arsenal of medication.
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
Could GlaxoSmithKline’s industry-leading dividend be at risk?
China revenue in Q3 increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales.
JOBS
IN THE PRESS